A select group of 19 large-cap BSE-listed companies achieved triple-digit growth in both profit and revenue during Q4FY26, indicating stron...

Pharma stocks surged on Wednesday, supported by strong earnings and a weakening rupee, even as Sensex and Nifty traded lower. The Nifty Pha...

Smallcap stocks, including IIFL Finance, Meesho, and GRSE, surged up to 7% on Wednesday, outperforming benchmark indices. This rally occurr...

Smallcap and midcap stocks outperformed benchmarks on Friday, with select names rallying up to 16% despite broader market weakness. Gains w...

Smallcap and midcap stocks surged on Wednesday, outperforming broader market indices with gains of around 1% each. This rally was fueled by...

Vedanta’s demerger has left investors awaiting the listing of its four newly carved-out entities, even as the parent stock continues to ris...

Geopolitical tensions in West Asia are manageable now. However, a prolonged US-Israel war against Iran could raise costs for petrochemical-...

Piramal Pharma Q3 Results: Revenue from operations rose 14% YoY driven by double digit growth across all the three businesses.

Piramal Pharma chairperson Nandini Piramal in an interview to ET said the company is aiming for mid-teen revenue growth and a meaningful im...

"During the year (FY23), the customer decision-making got delayed due to macro-economic environment and pipeline prioritisation based on li...

On like-to-like financials, the CDMO business that contributes 57% of revenues, declined 8% YoY to Rs 2164 crore. The complex hospital gene...

Piramal Pharma said while the YoY financials are not strictly comparable due to the non-inclusion of certain "non-common control transactio...

The complex hospital generic business that contributes one-third of revenues grew 12% YoY to Rs 562 crore. Piramal said it is witnessing st...

The pharmaceuticals business will get vertically demerged from Piramal Enterprises and consolidated under Piramal Pharma Ltd (PPL), the gro...

In March this year, Piramal Pharma Ltd entered into an agreement to acquire a 100 per cent stake in Hemmo Pharmaceuticals for an upfront co...

Consequent to the acquisition, Hemmo Pharmaceuticals Pvt Ltd would become a wholly-owned subsidiary of Piramal Pharma Ltd (PPL).

Given Piramal's track record of successful mergers and acquisitions, investors will be banking on the company's latest buyout, DRG, adding ...